scholarly journals Effect of Ki-67 assessment in the distribution of breast cancer subtypes: Evaluation in a cohort of Latin American patients

2017 ◽  
Vol 6 (4) ◽  
pp. 503-509 ◽  
Author(s):  
Alejandro Yábar ◽  
Rosa Meléndez ◽  
Silvia Muñoz ◽  
Hugo Deneo ◽  
Jimena Freire ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Latin American ◽  
Breast Cancer Subtypes ◽  
Ki 67 ◽  
Cancer Subtypes

scholarly journals Assessment of Ki-67 for Predicting Effective Prognosis in Breast Cancer Subtypes

2018 ◽  
Vol 24 (1) ◽  
pp. 9-14 ◽  
Author(s):  
Sangjung Park ◽  
Sunyoung Park ◽  
Jungho Kim ◽  
Sungwoo Ahn ◽  
Kwang Hwa Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Subtypes ◽  
Ki 67 ◽  
Cancer Subtypes

scholarly journals Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes

2019 ◽  
Vol 178 (2) ◽  
pp. 451-458 ◽  
Author(s):  
Giuseppe Viale ◽  
Amy E. Hanlon Newell ◽  
Espen Walker ◽  
Greg Harlow ◽  
Isaac Bai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Subtypes ◽  
Luminal A ◽  
Ki 67 ◽  
Cancer Subtypes ◽  
Luminal B

A prospective study of breast cancer subtypes in a cohort of Latin American patients.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e12615-e12615
Author(s):  
Alejandro Yabar ◽  
Rosa Melendez ◽  
Silvia Munoz ◽  
Hugo Deneo ◽  
Jimena Freire ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prospective Study ◽  
Latin American ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
A Prospective Study

scholarly journals Quantitative Values from Synthetic MRI Correlate with Breast Cancer Subtypes

2021 ◽  
Author(s):  
Toshiki Kazama ◽  
Taro Takahara ◽  
Thomas C. Kwee ◽  
Noriko Nakamura ◽  
Nobue Kumaki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Subtypes ◽  
Strong Positive Correlation ◽  
Characteristic Analysis ◽  
Luminal A ◽  
Ki 67 ◽  
Cancer Subtypes ◽  
Luminal B ◽  
Er Positive ◽  
Synthetic Mri

Abstract Purpose To correlate quantitative T1, T2, and proton density (PD) values from synthetic MRI with breast cancer subtypes. Methods Twenty-eight breast cancer patients underwent MRI of the breast including synthetic MRI. T1, T2, and PD values were correlated with Ki-67. T1, T2, and PD values were compared between estrogen receptor (ER) positive and ER negative cancers, and between Luminal A and Luminal B cancers. The effectiveness of T1, T2, and PD in differentiating the ER-negative from the ER-positive group and Luminal A from Luminal B cancers was evaluated using receiver operating characteristic analysis.Results Mean T2 relaxation of ER-negative cancers was significantly higher than that of ER-positive cancers (p < .05). The T1, T2, and PD values exhibited a strong positive correlation with Ki-67 (Pearson's r = 0.75, 0.69, and 0.60 respectively; p < .001). Among ER-positive cancers (n=23), T1, T2, and PD values of Luminal A cancers were significantly lower than those of Luminal B cancers (p < .05). The areas under the curve (AUCs) of T1, T2, and PD for discriminating ER-negative from ER-positive cancers were 0.74 (95% confidence interval (CI): 0.54-0.88), 0.87 (95% CI: 0.69-0.97), and 0.62 (95% CI: 0.42-0.79), respectively. The AUCs of T1, T2, and PD values for discriminating Luminal A from Luminal B cancers were 0.83 (95% CI: 0.61-0.95), 0.75 (95% CI: 0.52-0.90), and 0.75 (95% CI: 0.53-0.91), respectively.Conclusion Quantitative values from synthetic MRI significantly correlate with subtypes of invasive breast cancers and may classify subtypes with reasonably good accuracy.

Can Oncotype DX recurrence score (RS) be used in luminal A and luminal B breast cancer patients (pts) to predict the likely benefit of chemotherapy? A retrospective study in the Spanish population.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11006-e11006 ◽  
Author(s):  
Laura García-Estevez ◽  
Ana C Contreras ◽  
Isabel Calvo ◽  
Maria Fernandez Abad ◽  
Juan J de la Cruz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Oncotype Dx ◽  
Breast Cancer Subtypes ◽  
Treatment Recommendation ◽  
Nuclear Staining ◽  
Luminal A ◽  
Ki 67 ◽  
Cancer Subtypes ◽  
Luminal B

e11006 Background: The 2011 St Gallen guidelines recommend the use of Ki67 as a surrogate marker for luminal A and Luminal B breast cancer subtypes. Pts with luminal B subtypes should be considered for adjuvant chemotherapy. The guidelines also recognize the Oncotype DX RS as a predictor of chemotherapy benefit. The aim of this study is to assess the distribution of the RS in luminal A and luminal B breast cancer subtypes as defined by Ki67. Methods: Data from 91 pts with invasive breast cancer for which Oncotype DX results and pathology data were available. Pathological assessment was evaluated by the same pathologist. Estrogen (ER) and progesterone (PR) receptor was assessed by immunostaining (cut-off 10% nuclear staining). Ki67 was assessed by IHC [high (≥14%) and low (< 14%)]. Grading was performed by using Nottingham grading system. Results: Median age: 50 years (range: 35-78); premenopausal status: 49 pts (53.8%). Median tumor size: 1.5 cm (0, 3-6); Median of Ki 67 index: 15. 5 (range: 3-63); Median ER: 93 (35-100) and PR: 85(0-100). Sixty nine pts (75.8%) had negative-lymph nodes. RS was low in 56 (61. 5%) cases, intermediate in 24 (26. 4%), and high in 11 (12. 1%). The median RS was 16 (range 3-55). Forty six (51%) tumors were classified as luminal B (according to high Ki 67) and 38 (41.7%) as Luminal A. In the Luminal B group RS was low in 28 (61%) pts, intermediate in 10 (22%) and high in 8 (17%) while in the Luminal A group 23 (61%) had low RS; 13 (34%) intermediate and 2 (5%) high RS. RS changed the first treatment recommendation in 23 (50%) cases of Luminal B subtype vs. 10 (26%) cases in Luminal A subtype (p=0.013). Conclusions: Although based in a small case series, the results show that a substantial number (61%) pts with Luminal B breast cancer subtype had a low RS, therefore preserving them from adjuvant chemotherapy treatment. In addition, 5% of patients with Luminal A breast cancer had a high RS and thereby likely to benefit from chemotherapy. The wide range of RS in both Luminal B and Luminal A breast cancer subtypes confirm the important role of Oncotype DX in treatment decision- making.

scholarly journals Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival

PLoS ONE ◽  
2015 ◽  
Vol 10 (8) ◽  
pp. e0124658 ◽  
Author(s):  
Se Kyung Lee ◽  
Soo Youn Bae ◽  
Jun Ho Lee ◽  
Hyun-Chul Lee ◽  
Hawoo Yi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Low Risk ◽  
Breast Cancer Subtypes ◽  
Luminal A ◽  
Ki 67 ◽  
Term Survival ◽  
Long Term Survival ◽  
Cancer Subtypes

Can Oncotype DX Recurrence Score (RS) be used in Luminal A and Luminal B breast cancer patients (pts) to predict the likely benefit of chemotherapy? A retrospective unicentric study in Spanish population.

2013 ◽  
Vol 31 (26_suppl) ◽  
pp. 40-40 ◽  
Author(s):  
Laura G. Estevez ◽  
Isabel Calvo ◽  
Maria Fernandez-Abad ◽  
Juan Jose Cruz ◽  
Ana Suarez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Recurrence Score ◽  
Oncotype Dx ◽  
Breast Cancer Subtypes ◽  
Treatment Recommendation ◽  
Luminal A ◽  
Ki 67 ◽  
Cancer Subtypes ◽  
Luminal B

40 Background: The 2011 St Gallen guidelines recommend the use of Ki67 as a surrogate marker for luminal A and Luminal B breast cancer subtypes. Pts with luminal B subtypes should be treated with adjuvant chemotherapy. The guidelines also recognize the Oncotype DX RS as a predictor of chemotherapy benefit. The aim of this study is to assess the distribution of the RS in luminal A and luminal B breast cancer subtypes as defined by Ki67. Methods: Data from 131 pts with invasive breast cancer for which Oncotype DX results and pathology data were available. Pathological assessment was evaluated by the same pathologist. Estrogen (ER) and progesterone (PR) receptor was assessed by immunostaining (cut-off 10% nuclear staining). Ki67 was assessed by IHC [high (≥14%) and low (< 14%)]. Histological grade was performed by using Nottingham grading system. Results: Median age: 50 (range: 35-78); premenopausal status: 53 pts (44.2%). Median tumor size: 1, 5 cm (0, 3-5); Median of Ki 67 index: 15 (range: 3-63); 79 pts (66.4%) had negative-lymph nodes. Seventy (58.3%) tumors were classified as Luminal B (Ki 67 ≥14%) and 50 (41.7%) as Luminal A. Grade III were more common in Luminal B 14 (20.3%) than in Luminal A 1 pts (2%) patients (p=0.003). Chemotherapy was the first recommendation in 29 pts (41.4%) with Luminal B vs. 7 pts (14%) with Luminal A; hormonotherapy was the first recommendation in 32 pts (45.7%) with Luminal B and 37 pts (74%) in Luminal A (p =0.003). In the Luminal B group, Recurrence Score results was low in 42 (60%) pts, intermediate in 19 (27.1%) and high in 9 (12.9%) while in the Luminal A group 31 (62%) had low; 16 (32%) intermediate and 3 (6%) high Recurrence Score results (p=0.433). RS changed the first treatment recommendation in 35 (50%) cases of Luminal B subtype vs. 14 (28%) cases in Luminal A subtype (p=0.016). Conclusions: The results show that a substantial number (60%) pts with Luminal B breast cancer subtype had a low RS, therefore preserving them from adjuvant chemotherapy treatment. The wide range of RS in both Luminal B and Luminal A breast cancer subtypes confirm the important role of Oncotype DX in treatment decision making.

scholarly journals Immunohistochemical Expression of Androgen Receptors (AR) in Various Breast Cancer Subtypes

2019 ◽  
Vol 7 (8) ◽  
pp. 1259-1265 ◽  
Author(s):  
Nour El Hoda S. Ismael ◽  
Rasha A. Khairy ◽  
Suzan M. Talaat ◽  
Fatima A. Abd El-Fattah
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Androgen Receptors ◽  
Target Therapy ◽  
Tumour Size ◽  
Breast Cancer Subtypes ◽  
Clinicopathological Parameters ◽  
Malignant Tumours ◽  
Ki 67 ◽  
Cancer Subtypes

BACKGROUND: Breast carcinoma ranks the first among malignant tumours in females and is the chief cause of cancer-related mortality. Androgen in implicated in the induction of proliferation and growth of mammary cells through binding to their corresponding receptors. Androgens influence the risk of acquiring breast cancer through either direct binding to androgen receptors (AR) or indirectly through their transformation to estradiol or competing for steroid binding proteins. AIM: To study the expression of AR in various breast cancer subtypes and to elucidate its clinical significance by correlating it with clinicopathological parameters. METHODS: One hundred and fifty breast cancer cases were studied using AR immunohistochemistry, and its expression was correlated with different clinicopathologic parameters and with ER, PR, Her-2/neu and Ki 67 expression. RESULTS: AR was expressed in 91 breast carcinoma cases out of 150 examined. There was a statistically significant correlation between AR expression and tumour size, mitotic count, tumour necrosis, infiltrative borders, the hormonal status of the tumour and subsequently luminal subtypes (p < 0.05). A subset of studied TNBC (34.6%) also expressed AR. On the other hand, there was no significant correlation between AR expression and other clinicopathological parameters. CONCLUSION: Positive AR immunostaining was associated with favourable prognostic factors and luminal subtypes (A&B). Also, a subset of TNBC cases showed positive AR expression. These results introduce the current potent, next-generation AR- antagonist as possible target therapy in breast cancer. Further researches on AR expression in breast cancer are recommended on a larger scale with follow up and survival to validate the current results.

Sign in / Sign up

Export Citation Format

Share Document